Deciding whether to sell shares of Immunic depends entirely on an investor's personal financial strategy, risk tolerance, and evaluation of the company's clinical trial progress. Shareholders who are uncomfortable with the high volatility, cash burn pressures, and binary clinical trial risks inherent to small-cap biotechnology equities often choose to divest during restructuring phases or reverse-split events. Conversely, long-term investors bullish on the therapeutic potential of its oral immunology pipeline may opt to hold their positions, making it essential to review individual portfolio goals and professional financial guidance before transacting.